Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. NVDA
2. SPCX
3. META
4. MU
5. SPY
6. KOD
7. MIRM
8. USO
9. LLY
10. ACN

Go back to Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst
(NASDAQ: FULC) Delayed: 3.72 -0.02 (0.53%)
Previous Close $3.74    52 Week High $ 
Open $3.75    52 Week Low $ 
Day High $3.76    P/E N/A 
Day Low $3.71    EPS $ 
Volume 257,486